



## Expanded View Figures




**Figure EV1. miR-342 and EVL expression in breast cancer datasets.**

(A) Kaplan-Meier (KM) overall survival analysis on median split of miR-342 in ER+ (left) and TNBC (right) breast tumours (BRCA) from the TCGA database. Significance was measured by the Log-rank (Mantel-Cox) test. (B) Schematic of EVL gene locus showing the location of intronic miR-342. (C, D) Scatter plots showing positive correlations of miR-342-3p, miR-342-5p and EVL in TCGA and METABRIC datasets. Pearson correlation coefficients and associated *P* values are indicated. Relative expression of miR-342-3p and miR-342-5p in TCGA and METABRIC cohorts is shown. (E) MiR-342 expression in TCGA breast cancer subsets. Significance was measured by one-way ANOVA with Tukey post hoc test \*\*\*\**P* < 0.0001.




**Figure EV2. miR-342 expression and function in mouse and human breast cancer cell lines.**

(A) Relative expression of miR-342-3p in cells of the 4T1 panel measured by qPCR. The relative level of miR-342-3p in control (empty vector) or miR-342 overexpressing 4T1.2 cells is shown for comparison. Data are plotted as mean  $\pm$  SD of three technical replicates. (B) Proliferation assay of 4T1.2 control and miR-342 overexpressing cell lines. (C) Growth of 4T1.2 control and miR-342 overexpressing tumours following mammary fat pad implantation. The experimental endpoint was determined by equivalent tumour volume. Data are plotted as mean  $\pm$  SEM.  $n = 12$  mice/group. (D) Lung metastasis measured at experimental endpoint (d12 for Cont; d15 for miR-342) by genomic DNA qPCR of mouse tumour cells (mCherry) relative to total mouse cells (mouse Vimentin),  $n = 12$  mice/group. Significance was calculated by a two-tailed Mann-Whitney test. (E) Relative expression of miR-342-3p in control (empty vector) or miR-342 overexpressing 231HM cell lines. Data are plotted as mean  $\pm$  SD of three technical replicates. (F) Proliferation assay of 231HM control and miR-342 overexpressing cell lines, as measured by the CyQUANT fluorescence assay. Data are plotted as mean  $\pm$  SEM ( $n = 4$ ). (G) Relative expression of miR-342-3p and -5p in 231HM-i342 cells following 4 days of doxycycline (Dox) induction, as measured by qPCR. Data are plotted as mean  $\pm$  SD of three technical replicates. Average cycle thresholds (CT) are shown above each bar. (H) Growth assay of 231HM-i342 following 4 days of Dox induction (1 day pre-treatment). Mean  $\pm$  SD ( $n = 4$ ). (I) Relative expression of miR-342-3p and -5p in 231HM-i342 tumours at experimental endpoint measured by qPCR (day 30). Mean  $\pm$  SD ( $n = 6$ ). Average cycle thresholds (CT) are shown above each bar. (J) Volumes of 231HM-i342 tumours with or without Dox exposure. Mean  $\pm$  SEM ( $n = 6$ ). (K) Weight of 231HM-i342 tumours at experimental endpoint (day 30). The mean of six tumours per group is shown. Significance was calculated using a two-tailed Mann-Whitney test. (L, M) Relative cell migration (5 hr) and invasion (24 hr) of 231HM-i342 cells after 4 days of Dox induction. Mean of 4 biological replicates is shown. Significance was calculated by two-tailed Student's  $t$  test.



**Figure EV3. miR-342 inhibition in mouse and human breast cancer cell lines.**


(A) Phase contrast images of miR-342 high or miR-342 low expressing mouse and human breast cancer cell lines following 72 h transfection with control, miR-342-3p, or miR-342-5p Anti-miRs. Scale bars represent 50  $\mu$ m. (B) Schematic of miR-342 knockout (ko) approach using dual guide RNAs to cut out pre-miR-342 from the EVL host gene. (C) Gel showing PCR screen of genomic DNA isolated from MDA-MB-231 miR-342 ko clones (wt wild-type, h heterozygous). The size of the wild-type and full deletion of miR-342 based on the gRNA cut sites is shown. (D) Quantitation of miR-342-3p and -5p levels in WT and 4 different miR-342 ko clones. Cycle threshold (CT) of miR-342-3p in WT is shown. (E) Phase contrast images of WT and representative miR-342 ko clones. Scale bars represent 50  $\mu$ m. (F) Gels showing PCR screen of genomic DNA isolated from MDA-MB-231 miR-342 ko clones (clone numbers shown above; pool is cells collected after being transfected with gRNA#1 and #2). The size of the wild-type and full deletion of miR-342 based on the gRNA cut sites is shown. (G) Quantitation of miR-342-3p and -5p levels in WT pool (parental cells), a WT single clone, and 3 different miR-342 heterozygous clones. The Cycle Threshold (CT) of miR-342-3p and 5p expression in WT pool is shown in red.






#### Figure EV4. Identification of miR-342-5p target genes in TNBC.

(A) Pie chart showing the distribution of miR-342-5p Ago-HITS-CLIP peaks in 231HM cells by genomic location type. (B) Example of an Ago-HITS-CLIP peak in the AP2S1 gene. MiR-342-5p seed recognition sequences in the AP2S1 3'UTR are shown, with Ago-loaded miR-342-5p binding only to the 3'UTR binding site. Genome tracks represent the average read density of all replicates for each condition. (C) Distribution of miR-342-5p recognition sequences within Ago-HITS-CLIP peaks. The most enriched motif, corresponding to miR-342-5p, and the associated *P* value are shown. Background represents the occurrence of the motif on the opposite strand of the peak. (D) Volcano plot showing expression of genes altered by miR-342-5p transfection in 231HM cells (*n* = 2 biological replicates). Blue and red dots indicate significantly downregulated and upregulated genes, respectively, changing >twofold (*q* value < 0.05). (E) Venn diagram showing overlap of mRNAs significantly regulated by miR-342-5p with those having a miR-342-5p HITS-CLIP peak. For the overlapping genes, those that are repressed and contain 3'UTR binding sites are indicated. (F) Ranked bar chart showing change in expression of high-confidence miR-342-5p target genes upon miR-342-5p transfection. The location of the miR-342-5p HITS-CLIP is indicated by colour, with the dotted line marking the average degree of repression across all mRNAs. (G) Gene set enrichment analysis (GSEA) demonstrating increasing repression of miR-342-5p HITS-CLIP targets with a peak score of >50 or >100. Normalised enrichment scores (NES) and FDR are indicated. (H) Violin plots showing the degree of total repression (upper) and post-transcriptional repression (lower) for mRNA with different miR-342-3p seed types, locations and numbers. Significance was measured by one-way ANOVA with Tukey post hoc test (3 groups) or unpaired *t* test (2 groups). *P* values for gene expression for seed type 8-mer vs 7-mer (*P* = 0.0383), seed type 8-mer vs none (*P* = 0.0001), seed number multiple vs single (*P* = 0.0033) and other indicated comparisons are shown as ns—not significant, \**P* < 0.05, \*\**P* < 0.01, \*\*\**P* < 0.001, \*\*\*\**P* < 0.0001. *P* values for post-transcriptional expression for seed type 7-mer vs none (*P* = 0.0456), seed number multiple vs single (*P* = 0.0003) and other indicated comparisons are shown as ns—not significant, \**P* < 0.05, \*\*\**P* < 0.001, \*\*\*\**P* < 0.0001. (I) Venn diagram showing overlap between miR-342-3p and -5p direct targets. The overlapping genes are indicated.



**Figure EV5. Enrichment of pathways regulated by miR-342-3p and -5p in TNBC.**

(A, B) Normalised enrichment scores (NES) and FDR q-values from gene set enrichment analysis (GSEA) of differentially expressed genes following miR-342-3p or miR-342-5p transfection into 231HM cells. Gene sets with FDR < 0.01 are shown. (C) Quantitative PCR of E2F pathway genes, which are also direct miR-342-3p target genes, following doxycycline (Dox) induction of 231HM-i342 cells. (D) NES and FDR q-values from GSEA of differentially expressed genes in METABRIC TNBC tumours from the top vs bottom quartiles of miR-342-3p expression. Gene sets with FDR < 0.01 are shown.



**Figure EV6. Impact of miR-342 and the CDK4/6 inhibitor palbociclib on colony outgrowth.**

(A) Colony formation assays following doxycycline (Dox) induction of miR-342. The time 0 hr plate is shown in Fig. 5B. Data are quantitated in Fig. 5C,D. (B) Schematic of colony outgrowth assay involving cell detachment, agitation for increasing time to simulate anoikis, and limited dilution plating of cells. (C) Colony formation assays following control (neg) miRNA or transiently transfected miR-342-3p mimic into 231HM cells. (D, E) Quantitation of colony number and size with time of cell detachment after transfection of either negative (Neg) control miRNA or the miR-342-3p mimic (analysis on day 11). Data are plotted as mean  $\pm$  SD ( $n = 3$ ). Significance was measured with two-way ANOVA with Bonferroni post hoc tests.  $P$  values for colony number for neg miRNA vs miR-342-3p day 0 ( $P = 0.0032$ ), colony number for neg miRNA vs miR-342-3p day 6 ( $P = 0.0120$ ), colony size for neg miRNA vs miR-342-3p day 0 ( $P = 0.0001$ ), colony size for neg miRNA vs miR-342-3p day 6 ( $P = 0.0002$ ), colony size for neg miRNA vs miR-342-3p day 22 ( $P = 0.0099$ ) and other indicated comparisons are shown as \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , \*\*\*\* $P < 0.0001$ . (F) Colony formation assays following individual or co-treatment of 231HM-i342 cells with Dox to induce miR-342 and different doses of palbociclib (Palbo, harvest on d12). UT untreated. (G, H) Quantitation of colony number and size with the indicated treatments (red bars are co-treatments). Data are plotted as mean  $\pm$  SD ( $n = 3$ ). Significance was measured with one-way ANOVA with Bonferroni post hoc tests.  $P$  values for colony size for +Dox vs +Dox +25 nM Palbo ( $P = 0.0001$ ), +25 nM Palbo vs +Dox +25 nM Palbo ( $P = 0.0003$ ), +50 nM Palbo vs +Dox +50 nM Palbo ( $P = 0.0397$ ), +50 nM Palbo vs +100 nM Palbo ( $P = 0.0156$ ) and other indicated comparisons are shown as ns —not significant, \* $P < 0.05$ , \*\*\* $P < 0.001$ , \*\*\*\* $P < 0.0001$ . (I) Quantitative PCR of E2F1 (upper panel) and western blot of phosphorylated RB (lower panel) following treatment of 231HM-i342 cells with palbociclib and/or Dox for 24 h to measure immediate responses to treatment. Data are plotted as mean  $\pm$  SD ( $n = 3$ ). Significance was measured with one-way ANOVA with Bonferroni post hoc tests.  $P$  values for E2F1 for DMSO vs +50 nM Palbo ( $P = 0.0010$ ), DMSO vs +Dox ( $P = 0.0321$ ), +Dox vs +Dox +50 nM Palbo ( $P = 0.0100$ ) and other indicated comparisons are shown as \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , \*\*\*\* $P < 0.0001$ .